AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:02 2024-06-28 EDT			5-day change	1st Jan Change
12,356 ^GBX	+0.23%		-0.93%	+16.57%

06-27	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
06-26	European Equities Close Lower in Wednesday Trading	MT

ASTRAZENECA : Goldman Sachs reiterates its Buy rating

June 25, 2024 at 06:53 am

Goldman Sachs analyst Rajan Sharma maintains his Buy rating on the stock. The target price remains unchanged at GBX 15200.

Latest news about AstraZeneca PLC

US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27	RE
European Equities Close Lower in Wednesday Trading	06-26	MT
ASTRAZENECA : Deutsche Bank sticks Neutral	06-26	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	06-26	MT
AstraZeneca: Tagrisso approved in China for NSCLC	06-26	CF
AstraZeneca's Tagrisso plus chemo gets approval in China	06-26	AN
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment	06-26	RE
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	06-26	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	06-25	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	06-25	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	06-25
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	06-25	MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	06-25	MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	06-25	MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	06-25	MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	06-25	CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	06-25	RE
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	06-25	ZD
AstraZeneca: inconclusive trial for Infinzi in NSCL	06-25	CF
AstraZeneca: Tagrisso protocol approved in Japan	06-25	CF
AstraZeneca: inconclusive trial for Infinzei in NSCL	06-25	CF
AstraZeneca: conclusive trial in bladder cancer	06-25	CF
AstraZeneca details mixed findings from cancer drug trials	06-25	AN
Correction: AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT
AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

155.9 USD

Average target price

174.4 USD

Spread / Average Target

+11.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+16.57%	242B
ELI LILLY AND COMPANY	+55.78%	819B
JOHNSON & JOHNSON	-6.90%	351B
MERCK & CO., INC.	+16.53%	329B
ABBVIE INC.	+10.13%	298B
ROCHE HOLDING AG	+2.04%	225B
NOVARTIS AG	+13.31%	217B
AMGEN INC.	+8.60%	168B
PFIZER, INC.	-2.95%	158B
SANOFI	+0.20%	120B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Goldman Sachs reiterates its Buy rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals